BridgeBio Pharma (BBIO) PT Raised to $60 at Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $65.35 +0.48%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Mizuho analyst Salim Syed raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $60.00 (from $53.00) while maintaining a Outperform rating.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
- Envista Holdings Corp. (NVST) PT Lowered to $26 at Piper Sandler
- Aritzia (ATZ:CN) (ATZAF) PT Raised to Cdn$228 at UBS on Strong Growth
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
